{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:50:02Z","timestamp":1793836202082,"version":"4.6.1"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41581-024-00926-x","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T13:48:41Z","timestamp":1736948921000},"page":"330-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-7813","authenticated-orcid":false,"given":"Dieter","family":"Haffner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-3468","authenticated-orcid":false,"given":"Francesco","family":"Emma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-3388","authenticated-orcid":false,"given":"Lothar","family":"Seefried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6304","authenticated-orcid":false,"given":"Wolfgang","family":"H\u00f6gler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassim M.","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-941X","authenticated-orcid":false,"given":"Detlef","family":"Bockenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0578-2529","authenticated-orcid":false,"given":"Justine","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-4768","authenticated-orcid":false,"given":"Deborah","family":"Eastwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-3970","authenticated-orcid":false,"given":"Martin","family":"Biosse Duplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-7790","authenticated-orcid":false,"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Wicart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Ariceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8352-7312","authenticated-orcid":false,"given":"Elena","family":"Levtchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1283-411X","authenticated-orcid":false,"given":"Pol","family":"Harvengt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6470-7447","authenticated-orcid":false,"given":"Martha","family":"Kirchhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9523-8907","authenticated-orcid":false,"given":"Oliver","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chaussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1067-4976","authenticated-orcid":false,"given":"Lars","family":"Savendahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Briot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kamenick\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-4247","authenticated-orcid":false,"given":"Lars","family":"Rejnmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"926_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen, S. S., Brock-Jacobsen, B., Gram, J., Brixen, K. & Jensen, T. K. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur. J. Endocrinol. 160, 491\u2013497 (2009).","journal-title":"Eur. J. Endocrinol."},{"key":"926_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo, I. et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr. J. 62, 811\u2013816 (2015).","journal-title":"Endocr. J."},{"key":"926_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen, S., Johansson, S., R\u00e6der, H. & Bjerknes, R. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur. J. Endocrinol. 174, 125\u2013136 (2016).","journal-title":"Eur. J. Endocrinol."},{"key":"926_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1152\/physrev.00002.2011","volume":"92","author":"A Martin","year":"2012","unstructured":"Martin, A., David, V. & Quarles, L. D. Regulation and function of the FGF23\/klotho endocrine pathways. Physiol. Rev. 92, 131\u2013155 (2012).","journal-title":"Physiol. Rev."},{"key":"926_CR5","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter, T. O., Imel, E. A., Holm, I. A., Jan de Beur, S. M. & Insogna, K. L. A clinician\u2019s guide to X-linked hypophosphatemia. J. Bone Min. Res. 26, 1381\u20131388 (2011).","journal-title":"J. Bone Min. Res."},{"key":"926_CR6","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart, A. et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr. Connect 3, R13\u2013R30 (2014).","journal-title":"Endocr. Connect"},{"key":"926_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","volume":"87","author":"SS Beck-Nielsen","year":"2010","unstructured":"Beck-Nielsen, S. S. et al. Phenotype presentation of hypophosphatemic rickets in adults. Calcif. Tissue Int. 87, 108\u2013119 (2010).","journal-title":"Calcif. Tissue Int."},{"key":"926_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen, S. S. et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J. Rare Dis. 14, 58 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"926_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163259","volume":"8","author":"R Rana","year":"2023","unstructured":"Rana, R. et al. Impaired 1,25-dihydroxyvitamin D3 action underlies enthesopathy development in the Hyp mouse model of X-linked hypophosphatemia. JCI Insight 8, e163259 (2023).","journal-title":"JCI Insight"},{"key":"926_CR10","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.1210\/clinem\/dgab635","volume":"107","author":"C Volk","year":"2022","unstructured":"Volk, C. et al. Acute effects of an inorganic phosphorus additive on mineral metabolism and cardiometabolic risk factors in healthy subjects. J. Clin. Endocrinol. Metab. 107, e852\u2013e864 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR11","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00467-022-05505-5","volume":"37","author":"D Haffner","year":"2022","unstructured":"Haffner, D., Leifheit-Nestler, M., Grund, A. & Schnabel, D. Rickets guidance: part II \u2014 management. Pediatr. Nephrol. Berl. Ger. 37, 2289\u20132302 (2022).","journal-title":"Pediatr. Nephrol. Berl. Ger."},{"key":"926_CR12","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1210\/jc.2010-0589","volume":"95","author":"TO Carpenter","year":"2010","unstructured":"Carpenter, T. O. et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J. Clin. Endocrinol. Metab. 95, E352\u2013E357 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","volume":"127","author":"S DeLacey","year":"2019","unstructured":"DeLacey, S. et al. Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone 127, 386\u2013392 (2019).","journal-title":"Bone"},{"key":"926_CR14","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/jbmr.3992","volume":"35","author":"AL Lecoq","year":"2020","unstructured":"Lecoq, A. L. et al. Hyperparathyroidism in patients with X-linked hypophosphatemia. J. Bone Min. Res. 35, 1263\u20131273 (2020).","journal-title":"J. Bone Min. Res."},{"key":"926_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/000992289203100311","volume":"31","author":"U Alon","year":"1992","unstructured":"Alon, U., Lovell, H. B. & Donaldson, D. L. Nephrocalcinosis, hyperparathyroidism, and renal failure in familial hypophosphatemic rickets. Clin. Pediatr. 31, 180\u2013183 (1992).","journal-title":"Clin. Pediatr."},{"key":"926_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","volume":"58","author":"O Makitie","year":"2003","unstructured":"Makitie, O., Kooh, S. W. & Sochett, E. Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin. Endocrinol. Oxf. 58, 163\u2013168 (2003).","journal-title":"Clin. Endocrinol. Oxf."},{"key":"926_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner, D. et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat. Rev. Nephrol. 15, 435\u2013455 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"926_CR18","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter, T. O. et al. Burosumab therapy in children with X-linked hypophosphatemia. N. Engl. J. Med 378, 1987\u20131998 (2018).","journal-title":"N. Engl. J. Med"},{"key":"926_CR19","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter, T. O. et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J. Clin. Invest 124, 1587\u20131597 (2014).","journal-title":"J. Clin. Invest"},{"key":"926_CR20","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1359\/jbmr.090509","volume":"24","author":"Y Aono","year":"2009","unstructured":"Aono, Y. et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia. J. Bone Min. Res. 24, 1879\u20131888 (2009).","journal-title":"J. Bone Min. Res."},{"key":"926_CR21","unstructured":"Ultragenyx Pharmaceutical Inc. Ultragenyx and Kyowa Kirin Announce Crysvita\u00ae (burosumab-twza) Now Launched in the U.S. for the Treatment of X\u2013linked Hypophosphatemia (XLH) in Children and Adults https:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-and-kyowa-kirin-announce-crysvitar-burosumab-twza-now (2018)."},{"key":"926_CR22","unstructured":"European Medicines Agency. News and Events \u2013 New Medicine for Rare Bone Disease http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2017\/12\/news_detail_002874.jsp&mid=WC0b01ac058004d5c1 (2018)."},{"key":"926_CR23","unstructured":"FDA. Press Announcements \u2014 FDA Approves First Therapy for Rare Inherited Form of Rickets, X-Linked Hypophosphatemia. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm604810.htm (2018)."},{"key":"926_CR24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna, K. L. et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J. Bone Miner. Res, 33, 1383\u20131393 (2018).","journal-title":"J. Bone Miner. Res,"},{"key":"926_CR25","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.kint.2018.08.022","volume":"94","author":"F Emma","year":"2018","unstructured":"Emma, F. & Haffner, D. FGF23 blockade coming to clinical practice. Kidney Int. 94, 846\u2013848 (2018).","journal-title":"Kidney Int."},{"key":"926_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt, G. H. et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J. Clin. Epidemiol. 64, 395\u2013400 (2011).","journal-title":"J. Clin. Epidemiol."},{"key":"926_CR27","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1542\/peds.2004-1260","volume":"114","author":"American Academy of Pediatrics Steering Committee on Quality Improvement and Management.","year":"2004","unstructured":"American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics 114, 874\u2013877 (2004).","journal-title":"Pediatrics"},{"key":"926_CR28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/10408363.2017.1379945","volume":"54","author":"K Adeli","year":"2017","unstructured":"Adeli, K., Higgins, V., Trajcevski, K. & White-Al Habeeb, N. The Canadian laboratory initiative on pediatric reference intervals: a CALIPER white paper. Crit. Rev. Clin. Lab. Sci. 54, 358\u2013413 (2017).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"926_CR29","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1210\/clinem\/dgad597","volume":"109","author":"V Pott","year":"2023","unstructured":"Pott, V. et al. LMS-based pediatric reference values for parameters of phosphate homeostasis in the HARP cohort. J. Clin. Endocrinol. Metab. 109, 668\u2013679 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR30","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1001\/archinte.1991.00400080083015","volume":"151","author":"C G\u00f6k\u00e7e","year":"1991","unstructured":"G\u00f6k\u00e7e, C. et al. Use of random urine samples to estimate total urinary calcium and phosphate excretion. Arch. Intern. Med. 151, 1587\u20131588 (1991).","journal-title":"Arch. Intern. Med."},{"key":"926_CR31","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1093\/ndt\/gfab331","volume":"37","author":"L Derain Dubourg","year":"2022","unstructured":"Derain Dubourg, L. et al. Tubular phosphate handling: references from child to adulthood in the era of standardized serum creatinine. Nephrol. Dial. Transpl. 37, 2150\u20132156 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"926_CR32","unstructured":"European Society for Paediatric Nephrology. TmP\/GFR Calculator https:\/\/www.espn-online.org\/tmp-gfr-calculator\/ (2025)."},{"key":"926_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF00862587","volume":"2","author":"J Brodehl","year":"1988","unstructured":"Brodehl, J., Krause, A. & Hoyer, P. F. Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr. Nephrol. Berl. Ger. 2, 183\u2013189 (1988).","journal-title":"Pediatr. Nephrol. Berl. Ger."},{"key":"926_CR34","doi-asserted-by":"publisher","first-page":"dgaa267","DOI":"10.1210\/clinem\/dgaa267","volume":"105","author":"A Ewert","year":"2020","unstructured":"Ewert, A. et al. Bone and mineral metabolism in children with nephropathic cystinosis compared with other CKD entities. J. Clin. Endocrinol. Metab. 105, dgaa267 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR35","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1681\/ASN.2019111172","volume":"31","author":"P Florenzano","year":"2020","unstructured":"Florenzano, P. et al. Nephropathic cystinosis: a distinct form of CKD \u2014 mineral and bone disorder that provides novel insights into the regulation of FGF23. J. Am. Soc. Nephrol. 31, 2184\u20132192 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"926_CR36","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/jbmr.4702","volume":"37","author":"IR Hartley","year":"2022","unstructured":"Hartley, I. R. et al. Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia. J. Bone Min. Res. 37, 2174\u20132185 (2022).","journal-title":"J. Bone Min. Res."},{"key":"926_CR37","doi-asserted-by":"publisher","first-page":"17101","DOI":"10.1038\/nrdp.2017.101","volume":"3","author":"TO Carpenter","year":"2017","unstructured":"Carpenter, T. O. et al. Rickets. Nat. Rev. Dis. Prim. 3, 17101 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"926_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.13107\/jocr.2022.v12.i02.2650","volume":"12","author":"A Kaspiris","year":"2022","unstructured":"Kaspiris, A. et al. Hypophosphatemic osteomalacia in neurofibromatosis 1 associated with intracranial gliomas and congenital renal agenesis: a rare case report and review of the literature. J. Orthop. Case Rep. 12, 23\u201329 (2022).","journal-title":"J. Orthop. Case Rep."},{"key":"926_CR39","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/bcp.14643","volume":"87","author":"B Schaefer","year":"2021","unstructured":"Schaefer, B. et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 87, 2256\u20132273 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"926_CR40","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/alcalc\/agx041","volume":"52","author":"G Quintero-Platt","year":"2017","unstructured":"Quintero-Platt, G. et al. Alpha klotho and fibroblast growth factor-23 among alcoholics. Alcohol Alcohol. 52, 542\u2013549 (2017).","journal-title":"Alcohol Alcohol."},{"key":"926_CR41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2265.1992.tb02342.x","volume":"37","author":"JN Harvey","year":"1992","unstructured":"Harvey, J. N., Gray, C. & Belchetz, P. E. Oncogenous osteomalacia and malignancy. Clin. Endocrinol. 37, 379\u2013382 (1992).","journal-title":"Clin. Endocrinol."},{"key":"926_CR42","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/0002-9343(84)90112-8","volume":"77","author":"EA Ryan","year":"1984","unstructured":"Ryan, E. A. & Reiss, E. Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am. J. Med. 77, 501\u2013512 (1984).","journal-title":"Am. J. Med."},{"key":"926_CR43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.kint.2024.08.035","volume":"107","author":"M Brunkhorst","year":"2025","unstructured":"Brunkhorst, M. et al. Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2c. Kidney Int. 107, 116\u2013129 (2025).","journal-title":"Kidney Int."},{"key":"926_CR44","first-page":"136","volume":"50","author":"IH Kim","year":"2019","unstructured":"Kim, I. H., Singer, S. R. & Mupparapu, M. Review of cone beam computed tomography guidelines in North America. Quint. Int. 50, 136\u2013145 (2019).","journal-title":"Quint. Int."},{"key":"926_CR45","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.crad.2020.04.006","volume":"75","author":"RKW Schulze","year":"2020","unstructured":"Schulze, R. K. W. & Drage, N. A. Cone-beam computed tomography and its applications in dental and maxillofacial radiology. Clin. Radiol. 75, 647\u2013657 (2020).","journal-title":"Clin. Radiol."},{"key":"926_CR46","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0022034516677528","volume":"96","author":"M Biosse Duplan","year":"2017","unstructured":"Biosse Duplan, M. et al. Phosphate and vitamin D prevent periodontitis in X-linked hypophosphatemia. J. Dent. Res. 96, 388\u2013395 (2017).","journal-title":"J. Dent. Res."},{"key":"926_CR47","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1210\/jc.2003-030036","volume":"88","author":"O M\u00e4kitie","year":"2003","unstructured":"M\u00e4kitie, O. et al. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 88, 3591\u20133597 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR48","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00467-010-1705-9","volume":"26","author":"M Zivicnjak","year":"2011","unstructured":"Zivicnjak, M. et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr. Nephrol. 26, 223\u2013231 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"926_CR49","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1067\/mpd.2003.119","volume":"142","author":"C Chaussain-Miller","year":"2003","unstructured":"Chaussain-Miller, C. et al. Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. J. Pediatr. 142, 324\u2013331 (2003).","journal-title":"J. Pediatr."},{"key":"926_CR50","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00467-011-2046-z","volume":"27","author":"C Quinlan","year":"2012","unstructured":"Quinlan, C. et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr. Nephrol. 27, 581\u2013588 (2012).","journal-title":"Pediatr. Nephrol."},{"key":"926_CR51","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000464142","volume":"87","author":"M Lempicki","year":"2017","unstructured":"Lempicki, M. et al. Magnetic resonance imaging features as surrogate markers of X-linked hypophosphatemic rickets activity. Horm. Res. Paediatr. 87, 244\u2013253 (2017).","journal-title":"Horm. Res. Paediatr."},{"key":"926_CR52","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1172\/JCI111900","volume":"75","author":"RM Harrell","year":"1985","unstructured":"Harrell, R. M., Lyles, K. W., Harrelson, J. M., Friedman, N. E. & Drezner, M. K. Healing of bone disease in X-linked hypophosphatemic rickets\/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J. Clin. Invest. 75, 1858\u20131868 (1985).","journal-title":"J. Clin. Invest."},{"key":"926_CR53","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","volume":"325","author":"CF Verge","year":"1991","unstructured":"Verge, C. F. et al. Effects of therapy in X-linked hypophosphatemic rickets. N. Engl. J. Med. 325, 1843\u20131848 (1991).","journal-title":"N. Engl. J. Med."},{"key":"926_CR54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1507\/endocrj.47.163","volume":"47","author":"J Miyamoto","year":"2000","unstructured":"Miyamoto, J., Koto, S. & Hasegawa, Y. Final height of Japanese patients with X-linked hypophosphatemic rickets: effect of vitamin D and phosphate therapy. Endocr. J. 47, 163\u2013167 (2000).","journal-title":"Endocr. J."},{"key":"926_CR55","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1210\/jcem-52-3-463","volume":"52","author":"T Costa","year":"1981","unstructured":"Costa, T. et al. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J. Clin. Endocrinol. Metab. 52, 463\u2013472 (1981).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0022-3476(81)80951-1","volume":"99","author":"H Rasmussen","year":"1981","unstructured":"Rasmussen, H. et al. Long-term treatment of familial hypophosphatemic rickets with oral phosphate and 1 -hydroxyvitamin D3. J. Pediatr. 99, 16\u201325 (1981).","journal-title":"J. Pediatr."},{"key":"926_CR57","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0022-3476(87)80245-7","volume":"111","author":"PR Goodyer","year":"1987","unstructured":"Goodyer, P. R., Kronick, J. B., Jequier, S., Reade, T. M. & Scriver, C. R. Nephrocalcinosis and its relationship to treatment of hereditary rickets. J. Pediatr. 111, 700\u2013704 (1987).","journal-title":"J. Pediatr."},{"key":"926_CR58","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1515\/jpem-2014-0447","volume":"28","author":"M Keskin","year":"2015","unstructured":"Keskin, M., Sava\u015f-Erdeve \u015e, Sa\u011fsak, E., \u00c7etinkaya, S. & Aycan, Z. Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets. J. Pediatr. Endocrinol. Metab. 28, 1333\u20131337 (2015).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"926_CR59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-15-0661","volume":"174","author":"H Che","year":"2016","unstructured":"Che, H. et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur. J. Endocrinol. 174, 325\u2013333 (2016).","journal-title":"Eur. J. Endocrinol."},{"key":"926_CR60","first-page":"33","volume":"45","author":"M Berndt","year":"1996","unstructured":"Berndt, M. et al. Clinical course of hypophosphatemic rickets in 23 adults. Clin. Nephrol. 45, 33\u201341 (1996).","journal-title":"Clin. Nephrol."},{"key":"926_CR61","first-page":"879","volume":"75","author":"W Sullivan","year":"1992","unstructured":"Sullivan, W., Carpenter, T., Glorieux, F., Travers, R. & Insogna, K. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 75, 879\u2013885 (1992).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR62","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jocd.2005.11.001","volume":"9","author":"R Bhambri","year":"2006","unstructured":"Bhambri, R. et al. Changes in bone mineral density following treatment of osteomalacia. J. Clin. Densitom. 9, 120\u2013127 (2006).","journal-title":"J. Clin. Densitom."},{"key":"926_CR63","first-page":"38","volume":"116","author":"SL Teitelbaum","year":"1976","unstructured":"Teitelbaum, S. L., Rosenberg, E. M., Bates, M. & Avioli, L. V. The effects of phosphate and vitamin D therapy on osteopenic, hypophosphatemic osteomalacia of childhood. Clin. Orthop. 116, 38\u201347 (1976).","journal-title":"Clin. Orthop."},{"key":"926_CR64","doi-asserted-by":"publisher","first-page":"569530","DOI":"10.1155\/2014\/569530","volume":"2014","author":"SH Song","year":"2014","unstructured":"Song, S. H. et al. The significance of serum phosphate level on healing index and its relative effects in skeletally immature and mature patients with hypophosphatemic rickets. Biomed. Res. Int. 2014, 569530 (2014).","journal-title":"Biomed. Res. Int."},{"key":"926_CR65","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1210\/JC.2015-2199","volume":"100","author":"J Connor","year":"2015","unstructured":"Connor, J. et al. Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease. J. Clin. Endocrinol. Metab. 100, 3625\u20133632 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR66","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1210\/jc.2015-3229","volume":"100","author":"MJ Econs","year":"2015","unstructured":"Econs, M. J. Conventional therapy in adults with XLH improves dental manifestations, but not enthesopathy. J. Clin. Endocrinol. Metab. 100, 3622\u20133624 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR67","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel, E. A. et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393, 2416\u20132427 (2019).","journal-title":"Lancet"},{"key":"926_CR68","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart, A. et al. Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J. Clin. Endocrinol. Metab. 107, 813\u2013824 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR69","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale, A. A. et al. Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif. Tissue Int. 105, 271\u2013284 (2019).","journal-title":"Calcif. Tissue Int."},{"key":"926_CR70","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna, K. L. et al. Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J. Bone Min. Res. 34, 2183\u20132191 (2019).","journal-title":"J. Bone Min. Res."},{"key":"926_CR71","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","volume":"108","author":"A Ewert","year":"2023","unstructured":"Ewert, A. et al. Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia. J. Clin. Endocrinol. Metab. 108, e998\u2013e1006 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR72","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/cen.14832","volume":"99","author":"SL Ashrafzadeh-Kian","year":"2023","unstructured":"Ashrafzadeh-Kian, S. L. et al. The effect of burosumab on intact and C-terminal FGF23 measurements. Clin. Endocrinol. 99, 152\u2013157 (2023).","journal-title":"Clin. Endocrinol."},{"key":"926_CR73","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1515\/cclm-2020-0460","volume":"58","author":"ML Piketty","year":"2020","unstructured":"Piketty, M. L. et al. FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference. Clin. Chem. Lab. Med. 58, e267\u2013e269 (2020).","journal-title":"Clin. Chem. Lab. Med."},{"key":"926_CR74","doi-asserted-by":"crossref","unstructured":"Imel, E. A., et al. Burosumab versus phosphate\/active vitamin D in pediatric X-linked hypophosphatemia: a sub-group analysis by dose level. J. Clin. Endocrinol. Metab. 108, 2990\u20132998 (2023).","DOI":"10.1210\/clinem\/dgad230"},{"key":"926_CR75","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/archdischild-2022-324962","volume":"108","author":"EYX Walker","year":"2023","unstructured":"Walker, E. Y. X. et al. Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels. Arch. Dis. Child. 108, 379\u2013384 (2023).","journal-title":"Arch. Dis. Child."},{"key":"926_CR76","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte, M. P. et al. Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 7, 189\u2013199 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"926_CR77","doi-asserted-by":"crossref","unstructured":"Mao, M. et al. Growth curves for children with X-linked hypophosphatemia. J. Clin. Endocrinol. Metab. 105, 3243\u20133249 (2020).","DOI":"10.1210\/clinem\/dgaa495"},{"key":"926_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02590-5","volume":"17","author":"J Andr\u00e9","year":"2022","unstructured":"Andr\u00e9, J. et al. Growth hormone treatment improves final height in children with X-linked hypophosphatemia. Orphanet J. Rare Dis. 17, 444 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"926_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02562-9","volume":"17","author":"DA Ertl","year":"2022","unstructured":"Ertl, D. A. et al. Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone. Orphanet J. Rare Dis. 17, 412 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"926_CR80","unstructured":"AlQahtani, S. J. Atlas of tooth development and eruption. Queen Mary University of London https:\/\/www.qmul.ac.uk\/dentistry\/atlas\/ (2009)."},{"key":"926_CR81","doi-asserted-by":"publisher","first-page":"947814","DOI":"10.3389\/fendo.2022.947814","volume":"13","author":"R Brener","year":"2022","unstructured":"Brener, R., Zeitlin, L., Lebenthal, Y. & Brener, A. Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy. Front. Endocrinol. 13, 947814 (2022).","journal-title":"Front. Endocrinol."},{"key":"926_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10672","volume":"6","author":"M Gadion","year":"2022","unstructured":"Gadion, M. et al. Burosumab and dental abscesses in children with X-linked hypophosphatemia. JBMR Plus 6, e10672 (2022).","journal-title":"JBMR Plus"},{"key":"926_CR83","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar, A. et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J. Endocr. Soc. 3, 1321\u20131334 (2019).","journal-title":"J. Endocr. Soc."},{"key":"926_CR84","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0564","volume":"11","author":"C Nguyen","year":"2022","unstructured":"Nguyen, C. et al. Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration. Endocr. Connect. 11, e210564 (2022).","journal-title":"Endocr. Connect."},{"key":"926_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02452-0","volume":"17","author":"MIL Yanes","year":"2022","unstructured":"Yanes, M. I. L. et al. Health-related quality of life of X-linked hypophosphatemia in Spain. Orphanet J. Rare Dis. 17, 298 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"926_CR86","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","volume":"108","author":"R Padidela","year":"2021","unstructured":"Padidela, R. et al. Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif. Tissue Int. 108, 622\u2013633 (2021).","journal-title":"Calcif. Tissue Int."},{"key":"926_CR87","doi-asserted-by":"publisher","first-page":"bvac021","DOI":"10.1210\/jendso\/bvac021","volume":"6","author":"N Namba","year":"2022","unstructured":"Namba, N. et al. Safety and efficacy of burosumab in pediatric patients with X-linked hypophosphatemia: a phase 3\/4 open-label trial. J. Endocr. Soc. 6, bvac021 (2022).","journal-title":"J. Endocr. Soc."},{"key":"926_CR88","first-page":"361","volume":"1","author":"GI Baroncelli","year":"2004","unstructured":"Baroncelli, G. I. et al. Genetic advances, biochemical and clinical features and critical approach to treatment of patients with X-linked hypophosphatemic rickets. Pediatr. Endocrinol. Rev. 1, 361\u2013379 (2004).","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"926_CR89","doi-asserted-by":"publisher","first-page":"153892","DOI":"10.1016\/j.metabol.2019.03.009","volume":"103S","author":"A Rothenbuhler","year":"2020","unstructured":"Rothenbuhler, A., Schnabel, D., H\u00f6gler, W. & Linglart, A. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism 103S, 153892 (2020).","journal-title":"Metabolism"},{"key":"926_CR90","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jcph.1950","volume":"62","author":"SK Lee","year":"2022","unstructured":"Lee, S. K. et al. Population pharmacokinetics and pharmacodynamics of burosumab in adult and pediatric patients with X-linked hypophosphatemia. J. Clin. Pharmacol. 62, 87\u201398 (2022).","journal-title":"J. Clin. Pharmacol."},{"key":"926_CR91","unstructured":"European Medicines Agency. Crysvita - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/crysvita-epar-product-information_en.pdf (2024)."},{"key":"926_CR92","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1530\/EC-20-0291","volume":"9","author":"R Padidela","year":"2020","unstructured":"Padidela, R., Cheung, M. S., Saraff, V. & Dharmaraj, P. Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations. Endocr. Connect. 9, 1051\u20131056 (2020).","journal-title":"Endocr. Connect."},{"key":"926_CR93","doi-asserted-by":"publisher","first-page":"1034580","DOI":"10.3389\/fendo.2022.1034580","volume":"13","author":"MZ Mughal","year":"2022","unstructured":"Mughal, M. Z. et al. Burosumab for X-linked hypophosphatemia in children and adolescents: opinion based on early experience in seven European countries. Front. Endocrinol. 13, 1034580 (2022).","journal-title":"Front. Endocrinol."},{"key":"926_CR94","doi-asserted-by":"publisher","first-page":"105208","DOI":"10.1016\/j.jbspin.2021.105208","volume":"88","author":"J Bacchetta","year":"2021","unstructured":"Bacchetta, J. et al. X-linked hypophosphatemia and burosumab: practical clinical points from the French experience. Jt. Bone Spine 88, 105208 (2021).","journal-title":"Jt. Bone Spine"},{"key":"926_CR95","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1530\/EJE-21-0429","volume":"185","author":"VV Zhukouskaya","year":"2021","unstructured":"Zhukouskaya, V. V. et al. Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia. Eur. J. Endocrinol. 185, 475\u2013484 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"926_CR96","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s12325-022-02412-x","volume":"40","author":"T Kubota","year":"2023","unstructured":"Kubota, T. et al. Self-administration of burosumab in children and adults with X-linked hypophosphataemia in two open-label, single-arm clinical studies. Adv. Ther. 40, 1530\u20131545 (2023).","journal-title":"Adv. Ther."},{"key":"926_CR97","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/clinem\/dgab796","volume":"107","author":"K Dahir","year":"2022","unstructured":"Dahir, K. et al. Health care transition from pediatric- to adult-focused care in x-linked hypophosphatemia: expert consensus. J. Clin. Endocrinol. Metab. 107, 599\u2013613 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR98","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1172\/JCI36479","volume":"118","author":"LD Quarles","year":"2008","unstructured":"Quarles, L. D. Endocrine functions of bone in mineral metabolism regulation. J. Clin. Invest. 118, 3820\u20133828 (2008).","journal-title":"J. Clin. Invest."},{"key":"926_CR99","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0002-9343(91)90507-T","volume":"90","author":"IR Reid","year":"1991","unstructured":"Reid, I. R. et al. X-linked hypophosphatemia: skeletal mass in adults assessed by\u00a0histomorphometry, computed tomography, and absorptiometry. Am. J. Med. 90, 63\u201369 (1991).","journal-title":"Am. J. Med."},{"key":"926_CR100","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jocd.2014.01.003","volume":"17","author":"NJ Crabtree","year":"2014","unstructured":"Crabtree, N. J. et al. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. J. Clin. Densitom. 17, 225\u2013242 (2014).","journal-title":"J. Clin. Densitom."},{"key":"926_CR101","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","volume":"32","author":"S Giannini","year":"2021","unstructured":"Giannini, S. et al. Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review. Osteoporos. Int. 32, 1937\u20131949 (2021).","journal-title":"Osteoporos. Int."},{"key":"926_CR102","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1590\/S0036-36342009000700004","volume":"51","author":"JP Bonjour","year":"2009","unstructured":"Bonjour, J. P., Chevalley, T., Ferrari, S. & Rizzoli, R. The importance and relevance of peak bone mass in the prevalence of osteoporosis. Salud Publica Mex. 51, S5\u2013S17 (2009).","journal-title":"Salud Publica Mex."},{"key":"926_CR103","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002676","volume":"9","author":"P Kamenicky","year":"2023","unstructured":"Kamenicky, P. et al. Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open. 9, e002676 (2023).","journal-title":"RMD Open."},{"key":"926_CR104","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001714","volume":"7","author":"K Briot","year":"2021","unstructured":"Briot, K. et al. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open. 7, e001714 (2021).","journal-title":"RMD Open."},{"key":"926_CR105","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00223-022-01006-7","volume":"111","author":"ML Brandi","year":"2022","unstructured":"Brandi, M. L. et al. Efficacy of burosumab in adults with X-linked hypophosphatemia (XLH): a post Hoc subgroup analysis of a randomized double-blind placebo-controlled phase 3 study. Calcif. Tissue Int. 111, 409\u2013418 (2022).","journal-title":"Calcif. Tissue Int."},{"key":"926_CR106","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1210\/clinem\/dgac732","volume":"108","author":"H Kato","year":"2023","unstructured":"Kato, H. et al. Effect of conventional treatment on dental complications and ectopic ossifications among 30 adults with XLH. J. Clin. Endocrinol. Metab. 108, 1405\u20131414 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR107","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/clinem\/dgac518","volume":"108","author":"TJ Weber","year":"2022","unstructured":"Weber, T. J. et al. Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia. J. Clin. Endocrinol. Metab. 108, 155\u2013165 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR108","doi-asserted-by":"crossref","unstructured":"Herv\u00e9, A., et al. Improved oral health in adults with X-linked hypophosphatemia treated with burosumab. J. Clin. Endocrinol. Metab. dgae398 (2024).","DOI":"10.1210\/clinem\/dgae398"},{"key":"926_CR109","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1210\/clinem\/dgad440","volume":"109","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Efficacy and safety of burosumab in X-linked hypophosphatemia. J. Clin. Endocrinol. Metab. 109, 293\u2013302 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR110","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3945\/ajcn.112.053934","volume":"98","author":"MS Calvo","year":"2013","unstructured":"Calvo, M. S. & Uribarri, J. Public health impact of dietary phosphorus excess on bone and cardiovascular health in the general population. Am. J. Clin. Nutr. 98, 6\u201315 (2013).","journal-title":"Am. J. Clin. Nutr."},{"key":"926_CR111","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel, E. A. et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J. Clin. Endocrinol. Metab. 100, 2565\u20132573 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR112","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/mab.2022.0026","volume":"42","author":"A Marcellino","year":"2023","unstructured":"Marcellino, A. et al. Efficacy of burosumab every 2 weeks in an adult with X-linked hypophosphatemia: should we learn from children? Monoclon. Antib. Immunodiagn. Immunother. 42, 104\u2013108 (2023).","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"926_CR113","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1210\/jc.2014-2017","volume":"99","author":"TO Carpenter","year":"2014","unstructured":"Carpenter, T. O. et al. Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 99, 3103\u20133111 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR114","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0022-3476(05)82149-3","volume":"118","author":"A Bettinelli","year":"1991","unstructured":"Bettinelli, A., Bianchi, M. L., Mazzucchi, E., Gandolini, G. & Appiani, A. C. Acute effects of calcitriol and phosphate salts on mineral metabolism in children with hypophosphatemic rickets. J. Pediatr. 118, 372\u2013376 (1991).","journal-title":"J. Pediatr."},{"key":"926_CR115","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s004670050669","volume":"13","author":"TD Blydt-Hansen","year":"1999","unstructured":"Blydt-Hansen, T. D., Tenenhouse, H. S. & Goodyer, P. PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatr. Nephrol. Berl. Ger. 13, 607\u2013611 (1999).","journal-title":"Pediatr. Nephrol. Berl. Ger."},{"key":"926_CR116","doi-asserted-by":"publisher","first-page":"274","DOI":"10.14310\/horm.2002.1277","volume":"9","author":"MP Yavropoulou","year":"2010","unstructured":"Yavropoulou, M. P. et al. Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. Horm. Athens Greece 9, 274\u2013278 (2010).","journal-title":"Horm. Athens Greece"},{"key":"926_CR117","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1210\/endo-118-1-441","volume":"118","author":"LK Vaughn","year":"1986","unstructured":"Vaughn, L. K., Meyer, R. A. & Meyer, M. H. Increased metabolic rate in X-linked hypophosphatemic mice. Endocrinology 118, 441\u2013445 (1986).","journal-title":"Endocrinology"},{"key":"926_CR118","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cmet.2012.11.001","volume":"16","author":"B Angelin","year":"2012","unstructured":"Angelin, B., Larsson, T. E. & Rudling, M. Circulating fibroblast growth factors as metabolic regulators-a critical appraisal. Cell Metab. 16, 693\u2013705 (2012).","journal-title":"Cell Metab."},{"key":"926_CR119","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/jc.2015-2175","volume":"101","author":"CF Munns","year":"2016","unstructured":"Munns, C. F. et al. Global consensus recommendations on prevention and management of nutritional rickets. J. Clin. Endocrinol. Metab. 101, 394\u2013415 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR120","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/ndt\/gfx065","volume":"32","author":"R Shroff","year":"2017","unstructured":"Shroff, R. et al. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2\u20135 and on dialysis. Nephrol. Dial. Transpl. 32, 1098\u20131113 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"926_CR121","unstructured":"EFSA Panel on Dietetic Products, Nutrition and Allergies. Draft Scientific Opinion on Dietary Reference Values for Calcium https:\/\/www.efsa.europa.eu\/sites\/default\/files\/consultation\/150114.pdf (European Food Safety Authority, 2024)."},{"key":"926_CR122","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2215\/CJN.04981107","volume":"3","author":"US Alon","year":"2008","unstructured":"Alon, U. S. et al. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin. J. Am. Soc. Nephrol. 3, 658\u2013664 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"926_CR123","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1530\/EJE-08-0383","volume":"159","author":"H R\u00e6der","year":"2008","unstructured":"R\u00e6der, H., Shaw, N., Netelenbos, C. & Bjerknes, R. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. Eur. J. Endocrinol. 159, S101\u2013S105 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"926_CR124","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00467-018-4116-y","volume":"34","author":"BA Warady","year":"2019","unstructured":"Warady, B. A. et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. Pediatr. Nephrol. 34, 475\u2013486 (2019).","journal-title":"Pediatr. Nephrol."},{"key":"926_CR125","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00467-012-2364-9","volume":"28","author":"F Santos","year":"2013","unstructured":"Santos, F. et al. Hypophosphatemia and growth. Pediatr. Nephrol. 28, 595\u2013603 (2013).","journal-title":"Pediatr. Nephrol."},{"key":"926_CR126","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1074\/jbc.M112.410043","volume":"288","author":"M Kawai","year":"2013","unstructured":"Kawai, M. et al. FGF23 suppresses chondrocyte proliferation in the presence of soluble \u03b1-Klotho both in vitro and in vivo. J. Biol. Chem. 288, 2414\u20132427 (2013).","journal-title":"J. Biol. Chem."},{"key":"926_CR127","doi-asserted-by":"publisher","first-page":"8349","DOI":"10.1096\/fj.201802007R","volume":"33","author":"R Fuente","year":"2019","unstructured":"Fuente, R. et al. MAPK inhibition and growth hormone: a promising therapy in XLH. FASEB J. 33, 8349\u20138362 (2019).","journal-title":"FASEB J."},{"key":"926_CR128","first-page":"1165","volume":"145","author":"DM Wilson","year":"1991","unstructured":"Wilson, D. M. et al. Growth hormone therapy in hypophosphatemic rickets. Am. J. Dis. Child. 1960 145, 1165\u20131170 (1991).","journal-title":"Am. J. Dis. Child. 1960"},{"key":"926_CR129","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0022-3476(95)70070-6","volume":"127","author":"G Saggese","year":"1995","unstructured":"Saggese, G., Baroncelli, G. I., Bertelloni, S. & Perri, G. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density. J. Pediatr. 127, 395\u2013402 (1995).","journal-title":"J. Pediatr."},{"key":"926_CR130","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s004670050340","volume":"11","author":"GS Reusz","year":"1997","unstructured":"Reusz, G. S. et al. X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone. Pediatr. Nephrol. 11, 573\u2013577 (1997).","journal-title":"Pediatr. Nephrol."},{"key":"926_CR131","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1542\/peds.100.5.879","volume":"100","author":"MG Seikaly","year":"1997","unstructured":"Seikaly, M. G., Brown, R. & Baum, M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics 100, 879\u2013884 (1997).","journal-title":"Pediatrics"},{"key":"926_CR132","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ghir.2017.08.001","volume":"36","author":"A Rothenbuhler","year":"2017","unstructured":"Rothenbuhler, A. et al. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). Growth Horm. IGF Res. 36, 11\u201315 (2017).","journal-title":"Growth Horm. IGF Res."},{"key":"926_CR133","doi-asserted-by":"publisher","first-page":"E2097","DOI":"10.1210\/jc.2011-0399","volume":"96","author":"M \u017divi\u010dnjak","year":"2011","unstructured":"\u017divi\u010dnjak, M. et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J. Clin. Endocrinol. Metab. 96, E2097\u2013E2105 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR134","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00467-017-3820-3","volume":"33","author":"N Meyerhoff","year":"2018","unstructured":"Meyerhoff, N. et al. Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. Pediatr. Nephrol. Berl. Ger. 33, 447\u2013456 (2018).","journal-title":"Pediatr. Nephrol. Berl. Ger."},{"key":"926_CR135","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40122-021-00235-2","volume":"10","author":"SN El-Tallawy","year":"2021","unstructured":"El-Tallawy, S. N. et al. Management of musculoskeletal pain: an update with emphasis on chronic musculoskeletal pain. Pain. Ther. 10, 181\u2013209 (2021).","journal-title":"Pain. Ther."},{"key":"926_CR136","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.apmr.2008.04.009","volume":"89","author":"NE Walsh","year":"2008","unstructured":"Walsh, N. E. et al. Standards of care for acute and chronic musculoskeletal pain: the Bone and Joint Decade (2000\u20132010). Arch. Phys. Med. Rehabil. 89, 1830\u20131845 (2008).","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"926_CR137","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/bfm.2020.0068","volume":"15","author":"J Saito","year":"2020","unstructured":"Saito, J. et al. Belimumab concentrations in maternal serum and breast milk during breastfeeding and the safety assessment of the infant: a case study. Breastfeed. Med. 15, 475\u2013477 (2020).","journal-title":"Breastfeed. Med."},{"key":"926_CR138","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.arcped.2021.09.003","volume":"28","author":"FD Rocco","year":"2021","unstructured":"Rocco, F. D. et al. Orthopedic and neurosurgical care of X-linked hypophosphatemia. Arch. Pediatr. 28, 599\u2013605 (2021).","journal-title":"Arch. Pediatr."},{"key":"926_CR139","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1530\/EC-17-0154","volume":"6","author":"Gizard","year":"2017","unstructured":"Gizard et al. Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets (XLHR). Endocr. Connect. 6, 566\u2013573 (2017).","journal-title":"Endocr. Connect."},{"key":"926_CR140","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(24)01305-9","volume":"404","author":"P Kamenick\u00fd","year":"2024","unstructured":"Kamenick\u00fd, P., Briot, K., Munns, C. F. & Linglart, A. X-linked hypophosphataemia. Lancet 404, 887\u2013901 (2024).","journal-title":"Lancet"},{"key":"926_CR141","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/BPO.0000000000002393","volume":"43","author":"CW Grote","year":"2023","unstructured":"Grote, C. W. et al. Predicting rates of angular correction after hemiepiphysiodesis in patients with X-linked hypophosphatemic rickets. J. Pediatr. Orthop. 43, 379\u2013385 (2023).","journal-title":"J. Pediatr. Orthop."},{"key":"926_CR142","doi-asserted-by":"publisher","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","volume":"107","author":"MK Javaid","year":"2022","unstructured":"Javaid, M. K. et al. Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data. J. Clin. Endocrinol. Metab. 107, e1249\u2013e1262 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR143","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","volume":"32","author":"L Seefried","year":"2021","unstructured":"Seefried, L., Smyth, M., Keen, R. & Harvengt, P. Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteoporos. Int. 32, 7\u201322 (2021).","journal-title":"Osteoporos. Int."},{"key":"926_CR144","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00005792-198911000-00002","volume":"68","author":"IR Reid","year":"1989","unstructured":"Reid, I. R. et al. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine 68, 336\u2013352 (1989).","journal-title":"Medicine"},{"key":"926_CR145","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00198-022-06385-z","volume":"33","author":"M Scorcelletti","year":"2022","unstructured":"Scorcelletti, M. et al. Lower limb bone geometry in adult individuals with X-linked hypophosphatemia: an observational study. Osteoporos. Int. 33, 1601\u20131611 (2022).","journal-title":"Osteoporos. Int."},{"key":"926_CR146","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jor.2018.12.007","volume":"16","author":"ES Mills","year":"2019","unstructured":"Mills, E. S., Iorio, L., Feinn, R. S., Duignan, K. M. & Macica, C. M. Joint replacement in X-linked hypophosphatemia. J. Orthop. 16, 55\u201360 (2019).","journal-title":"J. Orthop."},{"key":"926_CR147","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3928\/01477447-20240122-02","volume":"47","author":"TG Costales","year":"2024","unstructured":"Costales, T. G. & Dalury, D. F. Four-year outcomes of cementless versus cemented fixation of a newly introduced total knee arthroplasty design. Orthopedics 47, 161\u2013166 (2024).","journal-title":"Orthopedics"},{"key":"926_CR148","doi-asserted-by":"publisher","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","volume":"107","author":"LM Ward","year":"2022","unstructured":"Ward, L. M. et al. Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia. J. Clin. Endocrinol. Metab. 107, e3241\u2013e3253 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"926_CR149","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jbmr.3614","volume":"34","author":"A Rothenbuhler","year":"2019","unstructured":"Rothenbuhler, A. et al. High incidence of cranial synostosis and Chiari I malformation in children with X-linked hypophosphatemic rickets (XLHR). J. Bone Min. Res. 34, 490\u2013496 (2019).","journal-title":"J. Bone Min. Res."},{"key":"926_CR150","volume":"15","author":"L Alkhatib","year":"2023","unstructured":"Alkhatib, L. et al. Lifestyle modifications and nutritional and therapeutic interventions in delaying the progression of chronic kidney disease: a review. Cureus 15, e34572 (2023).","journal-title":"Cureus"},{"key":"926_CR151","first-page":"461","volume":"68","author":"P Sass","year":"2003","unstructured":"Sass, P. & Hassan, G. Lower extremity abnormalities in children. Am. Fam. Physician 68, 461\u2013468 (2003).","journal-title":"Am. Fam. Physician"},{"key":"926_CR152","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00431-014-2454-8","volume":"174","author":"V Saraff","year":"2015","unstructured":"Saraff, V. et al. Sex-, age-, and height-specific reference curves for the 6-min walk test in healthy children and adolescents. Eur. J. Pediatr. 174, 837\u2013840 (2015).","journal-title":"Eur. J. Pediatr."},{"key":"926_CR153","doi-asserted-by":"crossref","unstructured":"den Bakker, E., B\u00f6kenkamp, A., & Haffner, D. Assessment of kidney function in children. Pediatr. Clin. North Am. 69, 1017\u20131035 (2022).","DOI":"10.1016\/j.pcl.2022.07.001"},{"key":"926_CR154","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1172\/JCI107774","volume":"54","author":"CY Pak","year":"1974","unstructured":"Pak, C. Y., Oata, M., Lawrence, E. C. & Snyder, W. The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria. J. Clin. Invest. 54, 387\u2013400 (1974).","journal-title":"J. Clin. Invest."}],"updated-by":[{"DOI":"10.1038\/s41581-025-00939-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000}}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00926-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00926-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00926-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:02:02Z","timestamp":1745323322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00926-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":154,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1038\/s41581-024-00926-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41581-025-00939-0","asserted-by":"object"}]},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"12 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41581-025-00939-0","URL":"https:\/\/doi.org\/10.1038\/s41581-025-00939-0","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.B. and L.S. receive support for research and consultancy from Kyowa Kirin. A.L., M.B.D., L.R. and C.C. receive research support from Kyowa Kirin. D.H. receives research support and speaker and consultant fees from Kyowa Kirin. The institution of A.L. (AP-HP) receives her speaker and consultant fees from Kyowa Kirin. G.A. receives speaker and consultant fees from Kyowa Kirin. F.E., E.L., P.K., K.B., D.S., M.L.B. and K.B. receive consultation fees from Kyowa Kirin. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}